Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity

Bronchopulmonary Dysplasia Clinical Trial

Official title:

Candidate Genes Associated With Susceptibility to Bronchopulmonary Dysplasia and Retinopathy of Prematurity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01780155
• Other study ID #: 999913031
• Secondary ID: 13-E-N031
• Status: Completed
• Start date: June 24, 2013
• Est. completion date: August 1, 2020

Study information

• Verified date: August 2019
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

• Some premature babies develop bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP). BPD and ROP are long-term chronic diseases of the lungs and eyes, respectively. BPD is associated with receiving mechanical ventilation to treat respiratory distress syndrome, and causes lung inflammation and scarring. ROP is caused by poor development of blood vessels in the eyes, and may lead to blindness. Because not all premature babies develop BPD or ROP, researchers want to study the genes that could be associated with these diseases. They will look at both premature infants and their parents to see if there is a genetic component to BPD and ROP.

Objectives:

• To study genes that may be associated with BPD and ROP.

Eligibility:

• Premature babies born with a weight less than or equal to 1,250 grams.

• Parents of the premature babies.

Design:

• Parents will answer questions about the mother s health and pregnancy.

• Delivery and medical information will be collected during the baby s hospitalization for the first month after birth.

• Parents will provide a saliva sample from the inside of the cheek.

• A saliva sample will also be collected from the baby within 28 days of birth. If the baby needs tracheal aspiration (removal of fluid from the throat), tracheal fluid samples will also be collected.

• Parents will have followup interviews about their child s health 6 months, 12 months, and yearly for up to 6 years after birth.

• This is a genetic study only. Treatment will not be provided as part of this study.

Description:

Understanding the role of susceptibility genes for risk of BPD and ROP may lead to immediate identification of populations who require personalized medical care, and to the assessment of innovative prophylactic and therapeutic interventions in the future. Our purpose is to establish in our hospital network a prospective cohort of triads composed of premature newborns with a birth weight less than or equal to 1250 g and their parents, to examine the role of candidate susceptibility genes in the development of BPD and ROP. Our hypothesis is that the presence of single-nucleotide polymorphisms in candidate genes is associated with differential susceptibility to BPD and ROP. As an initial model, a loss-of-function substitution at position -617 of the NRF2 promoter region is hypothesized to be associated with a greater risk of severe BPD and prethreshold ROP in premature infants with a birth weight less than or equal to 1250 g.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1068
• Est. completion date: August 1, 2020
• Est. primary completion date: July 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

• INCLUSION CRITERIA:

Premature newborns with a birth weight less than or equal to 1250 g and their parents from the participating institutions that comprise the Fundacion Infant hospital network will be enrolled in this study after signing the informed consent.

EXCLUSION CRITERIA:

Premature newborns with a birth weight less than or equal to 1250 g with cyanotic congenital heart disease, congenital anomalies of the respiratory tract (for example, tracheoesophageal fistula, pulmonary hypoplasia, diaphragmatic hernia), eye malformations, or congenital immunodeficiencies. Newborns from parents (mother and/or father) who used in vitro fertilization products from donor banks will also be excluded from participating in the study.

Related Conditions & MeSH terms

• Bronchopulmonary Dysplasia
• Hyperplasia
• Premature Birth
• Prematurity
• Pulmonary Disease
• Retinal Diseases
• Retinopathy of Prematurity

Locations

Country	Name	City	State
Argentina	Clinica Y Maternidad	Buenos Aires
Argentina	Fundacion Infant	Buenos Aires
Argentina	Hospital Italiano de Buenos Aires	Buenos Aires
Argentina	Instituto Medico de Obstretricia (IMO)	Buenos Aires
Argentina	Sanatario de los Arcos	Buenos Aires
Argentina	Sanatorio de la Trinidad	Buenos Aires
Argentina	Sanatorio Otamendi y Miroli	Buenos Aires
United States	NIEHS, Research Triangle Park	Research Triangle Park	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Environmental Health Sciences (NIEHS)

Countries where clinical trial is conducted

United States,  Argentina, 

References & Publications (3)

Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. J Perinatol. 2004 Mar;24(3):164-8. — View Citation

Asikainen TM, Huang TT, Taskinen E, Levonen AL, Carlson E, Lapatto R, Epstein CJ, Raivio KO. Increased sensitivity of homozygous Sod2 mutant mice to oxygen toxicity. Free Radic Biol Med. 2002 Jan 15;32(2):175-86. — View Citation

Clyman R. Oxygen-saturation targets and outcomes in extremely preterm infants. J Pediatr. 2004 Mar;144(3):408. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bronchopulmonary dysplasia; retinopathy of prematurity		6 years